mavrilimumab   Click here for help

GtoPdb Ligand ID: 7785

Synonyms: CAM-3001 | KPL-301
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mavrilimumab targets CSF2RA (aka GM-CSFRα).
Peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis identifies mavrilimumab as antibody 6 in patent US8263075 [2].
Click here for help
1. Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D et al.. (2018)
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
Arthritis Rheumatol, 70 (5): 679-689. [PMID:29361199]
2. Cohen ES, Minter RR, Harrison PR, Sleeman MA, Nash AD, Fabri LJ. (2012)
Antibody molecule for human GM-CSF receptor alpha.
Patent number: US8263075. Assignee: Medimmune Limited. Priority date: 27/03/2006. Publication date: 11/09/2012.
3. Kiniksa Pharmaceuticals. 
Accessed on 04/03/2020. Modified on 04/03/2020.,
4. Nair JR, Edwards SW, Moots RJ. (2012)
Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy.
Expert Opin Biol Ther, 12 (12): 1661-8. [PMID:23094973]